Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Key Inclusion Criteria:

• Relapsed and/or refractory B-cell lymphoma (R/R BCL).

• At least 1 measurable lesion.

• Adequate organ and bone marrow (BM) function.

Key Exclusion Criteria:

• History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg,cervix, bladder, or breast) unless disease free and without anticancer therapy (withthe exception of hormonal therapy in the case of breast cancer) for at least 3years.

• History of Richter's transformation of chronic leukemic lymphoma, small lymphocyticlymphoma, or lymphoplasmacytic lymphoma.

• History of allogeneic stem cell transplant (allo-SCT).

• Auto-SCT within 6 weeks before the planned KITE-363 or KITE-753 infusion.

• Presence of fungal, bacterial, viral, or other infection that is uncontrolled orrequires intravenous (IV) antimicrobials for management.

• Known history of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) hepatitis B surface (HBs) antigen (HBsAg) positive infection, or hepatitis C (anti-hepatitis C virus [HCV] positive) infection.

• Individuals with detectable cerebrospinal fluid (CSF) malignant cells or brainmetastases or a history of central nervous system (CNS) lymphoma, primary CNSlymphoma, or spinal epidural involvement.

• History or presence of a CNS disorder.

• History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,active arrhythmia, New York Heart Association Class II or greater congestive heartfailure or other clinically significant cardiac disease within the 6 months beforeenrollment.

• Primary immunodeficiency.

• History of autoimmune disease resulting in or requiring systemic immunosuppressionand/or systemic disease-modifying agents within the last 2 years.

• History of non-line associated, clinically significant deep-vein thrombosis orpulmonary embolism requiring therapeutic anticoagulation within the 6 months beforeenrollment.

• Females of childbearing potential who are pregnant or breastfeeding because of thepotentially dangerous effects of the preparative chemotherapy on the fetus orinfant. Females who have undergone surgical sterilization or have beenpostmenopausal for at least 2 years are not considered to be of childbearingpotential.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.